SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix's upcoming earnings are sparking active debate, especially after the stock traded down in the after-hours session. While revenue was in line with estimates, EPS missed, and some community members are attributing the dip to a tax dispute in Brazil and broader concerns about content. A potential stock split and the impact of increased competition and advertising revenue are also key talking points.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending due to its acquisition of Railbird, a prediction market platform, sparking discussions about the company's expansion into new markets beyond sports betting. While some express excitement about this growth and potential, others are skeptical, citing concerns about profitability and regulatory challenges, with community members closely watching how this move impacts the stock's value.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending as the stock experiences a significant pullback, prompting community discussion about potential bottom levels and future catalysts. Despite the recent downturn, some investors express confidence in the company's long-term prospects, citing a major deal with Microsoft and overall growth in the AI sector. Community members are actively debating whether to buy the dip or wait for further price declines.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgical is trending due to anticipation surrounding its upcoming earnings report, with the community actively discussing potential outcomes and guidance. Bullish sentiment suggests the company will beat expectations, driven by strong global adoption of its da Vinci systems and procedure growth, despite concerns about tariffs and margin pressures. Traders are also closely monitoring unusual options activity and technical indicators for potential short-term opportunities.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending due to a proposed private offering of convertible senior notes, leading to community discussion about dilution and its impact on long-term holders; some view this as a strategic move to secure funding before positive catalysts, while others express concern about the company's financial management and potential for further offerings; the community is also debating the recent analyst downgrade and its effect on the stock's trajectory.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending amidst speculation of a potential acquisition, with Paramount Skydance reportedly interested in making a bid, although the deal's likelihood is debated. Community chatter revolves around potential offer prices and whether WBD will accept, with some anticipating a bidding war involving other major players like Netflix or Comcast. The stock's movement reflects investor uncertainty surrounding these ongoing acquisition rumors and what price a deal could actually happen at.

Texas Instruments Incorporated engages in the design and manufacture of semiconductors. It operates through the following segments: Analog, Embedded Processing, and Other. The Analog segment semiconductors change real-world signals, such as sound, temperature, pressure or images, by conditioning them, amplifying them and often converting them to a stream of digital data that can be processed by other semiconductors, such as embedded processors. The Embedded Processing segment involves handling specific tasks and can be optimized for various combinations of performance, power, and cost, depending on the application. The company was founded in 1930 and is headquartered in Dallas, TX.

Texas Instruments Inc.

Texas Instruments is trending following its latest earnings report, with revenue exceeding expectations but EPS falling slightly short, leading to mixed sentiment. The community is actively discussing whether the results justify the stock's valuation amidst broader concerns about the macro environment and potential tariff impacts. Some believe TXN is undervalued and poised for a rally, while others are wary of the company's guidance and competitive landscape.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

Minerva Neurosciences Inc

Minerva Neurosciences ($NERV) is trending due to a massive surge following news of a $200M financing deal aimed at advancing its schizophrenia treatment. Community chatter revolves around the potential for significant gains, while some traders caution about a possible pump and dump, leading to high volatility. The funding is viewed as a strong indicator of confidence in the drug's approval, sparking debates about its long-term potential versus short-term trading opportunities.

rYojbaba Co., Ltd. engages in providing consulting and health services to improve and restore physical and mental health diminished by work-related stress. It operates through the Labor Consulting Services and Health Services segments. The Labor Consulting Services segment provides labor and corporate consulting services to foster constructive employment relationships between companies and employees. The Health Services segment provides health services through osteopathic clinics and osteopathic beauty salons to alleviate physical ailments primarily created by work related stress. The company was founded by Masataka Sakai on January 5, 2015 and is headquartered in Fukuoka, Japan.

rYojbaba Co. Ltd.

rYojbaba Co., Ltd. 

rYojbaba Co., Ltd. ($RYOJ) is trending due to a significant surge in price and volume, prompting discussions about potential short squeezes and comparisons to other recent high-momentum stocks. The community is actively speculating on targets and potential sympathy plays, with some noting the stock's low float and recent IPO status. News of partnerships may be contributing to market stimulation.

Sweetgreen, Inc. owns and operates a chain of salad restaurants. It offers drinks, sides, local bowls, salads, plates, and warm bowls. The company was founded by Nicolas Jammet, Jonathan Neman, and Nathaniel E. Ru in November 2006 and is headquartered in Los Angeles, CA.

Sweetgreen Inc - Ordinary Shares - Class A

Sweetgreen ($SG) is trending as chatter suggests a potential short squeeze ahead of earnings, with community members noting high put/call ratios and significant options activity. Some investors believe the stock is oversold and undervalued, especially given its robotics technology from the SPYCE acquisition, while others are eyeing it as a sympathy play with other heavily shorted stocks like BYND making moves. Community members are actively discussing the potential for a gamma squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioXcel Therapeutics, Inc. (BTAI) announced on Wednesday that its BXCL501 demonstrated continued effects and consistent benefit with repeat dosing in the treatment of agitation associated with bipolar disorders or schizophrenia in a late-stage trial.BXCL501 is an investigational, orally dissolving film formulation of Dexmedetomidine, marketed by the company as Igalmi. While the primary objective of the trial was to ascertain the safety of the formulation in an at-home setting, the continued effects and consistent benefits observed with repeat dosing in the trial further support the potential of BXCL501 for use in the outpatient setting, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-reports-positive-topline-exploratory">said</a>.Shares of the company rose 3% in the pre-market session. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BTAI">BTAI stock</a> rose from ‘extremely bearish’ to ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘extremely low’ levels.BioXcel <a href="https://stocktwits.com/news-articles/markets/equity/bioxcel-sublingual-film-well-tolerated-in-bipolar-schizophrenia-trial-in-at-home-settings/chsU5sURdl5">reported</a> late last month that the drug was well-tolerated in the study. The company said that the data from the study will form the basis of a submission to the U.S. Food and Drug Administration (FDA) slated for the first quarter of 2026 and aimed at expanding the label for Dexmedetomidine in the at-home setting.“These positive results, along with the safety and tolerability data previously announced, reinforce BXCL501’s potential in the at-home setting where there is substantial unmet need with no FDA-approved options currently available,” said BioXcel CEO Vimal Mehta.The company said that a total of 246 patients were part of the trial, and 2,437 agitation episodes in 208 patients were treated. All patients were able to successfully self-administer the film, and an average of 11.7 agitation episodes were recorded per treated patient.Igalmi is already approved for the acute treatment of agitation associated with bipolar I or II disorder or schizophrenia in medically supervised settings.BTAI stock is down by 40% this year and by 59% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-edge-lower-ahead-of-inflation-data/chwkJpfRduc">Dow Futures Edge Lower As Investors Turn Cautious Ahead Of Inflation Data: ORCL, KLAR, HOOD, GME Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

BioXcel Stock Shoots Up 3% Pre-Market After Company Announces Positive Efficacy Data For Agitation Drug In Study

The company stated that the continued effects and consistent benefits observed with repeat dosing in the trial support the potential of BXCL501 for use in the outpatient setting. 

Equity

BioXcel Therapeutics, Inc. (BTAI) on Wednesday said that its late-stage trial evaluating the safety of the company’s BXCL501 as a treatment for agitation associated with bipolar disorders or schizophrenia in the at-home setting met its primary goal of being well-tolerated.BXCL501 is an investigational, orally dissolving film formulation of Dexmedetomidine. The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-announces-serenity-home-pivotal-phase-3">said</a> that the data from the study will form the basis of a submission to the U.S. Food and Drug Administration slated for the first quarter of 2026 and aimed at expanding the label for its dexmedetomidine sublingual film called Igalmi in the at-home setting.Igalmi is already approved for the acute treatment of agitation associated with bipolar I or II disorder or schizophrenia in medically supervised settings.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BTAI">BTAI stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:624/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_27_at_9_42_20_AM_png_54402b6e8c.webp" alt="BTAI's Sentiment Meter and Message Volume as of 9:42 a.m. ET on Aug. 27, 2025 | Source: Stocktwits" width="624" height="65"><figcaption>BTAI's Sentiment Meter and Message Volume as of 9:42 a.m. ET on Aug. 27, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user recommended buying the shares of the company.<stembedurl>https://stocktwits.com/Michael17711771/message/626688937</stembedurl>Another user opined that the study results are very promising long term.<stembedurl>https://stocktwits.com/They_call_me_tater_salad/message/626688733</stembedurl>BioXcel said that no discontinuations due to tolerability were observed in the arm of the study that received BXCL501.“By meeting its primary endpoint, the SERENITY At-Home Pivotal Phase 3 trial reinforces BXCL501’s potential to be safely used at home like it is already used in the previously FDA approved institutional setting. The unmet medical need in the at-home setting is significant with no FDA-approved treatments,” CEO Vimal Mehta said, while adding that the company believes the total addressable market is “significantly larger” than previously reported.The company said that a total of 246 patients were part of the trial, and 2,437 agitation episodes in 208 patients were treated. All patients were able to successfully self-administer the film, and an average of 11.7 agitation episodes were recorded per treated patient.The company said that available data demonstrate that treatment with BXCL501 regularly reduced symptoms of agitation throughout the trial. A greater percentage of patients experiencing mild, moderate, or severe agitation had full resolution of symptoms in the BXCL501 arm compared with placebo. Complete analyses of the full data set are ongoing and will be shared in time, the company said.BTAI stock is down by 24% this year and by 57% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/mannkind-united-therapeutics-expand-agreement-to-develop-second-investigational-molecule-together/chsURMTRdkC">MannKind, United Therapeutics Expand Agreement To Develop A Second Investigational Molecule Together</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

BioXcel’s Sublingual Film Well-Tolerated In Bipolar, Schizophrenia Trial In At-Home Settings, Retail Says Buy Now Or Regret Later

The company said that no discontinuations due to tolerability were observed in the arm of the study that received BXCL501.

BioXcel Therapeutics drew sharp retail-trader attention early Wednesday as the company gears up to release topline results later in the day for its experimental therapy to treat agitation linked to bipolar disorders and schizophrenia outside of clinical settings.The report from its SERENITY At-Home Phase 3 safety trial will reveal detailed effects of BXCL501, marketed as Igalmi, the company's sublingual film formulation of dexmedetomidine. The company plans to hold an investor call and webcast at 8 a.m. ET to discuss the data.The announcement about the release, made late Tuesday, triggered a 19% spike in&nbsp;<a href="https://stocktwits.com/symbol/BTAI">BioXcel's stock</a> after the bell, sending the ticker to the top of trending symbols on Stocktwits, accompanied by a 118% surge in 24-hour message volume. Sentiment, however, was ‘neutral’ as of the last reading.<figure class="image"><img style="aspect-ratio:1310/194;" src="https://news.stocktwits-cdn.com/BTAI_stock_sentiment_and_message_volume_on_Aug_27_png_6d08b1cb22.webp" alt="BTAI stock sentiment and message volume on Aug 27.png" width="1310" height="194"><figcaption>BTAI stock sentiment and message volume on Aug 27 as of 3:30 am ET | source: Stocktwits</figcaption></figure>Last week, BioXcel captured investors' attention after the company<a href="https://stocktwits.com/news-articles/markets/equity/bio-xcel-stock-in-focus-fda-issues-positive-early-feedback-ahead-of-key-meeting-on-expanded-psychiatric-label-1/chsOR5KRdQ1">&nbsp;said</a> the FDA had provided positive preliminary comments for Igalmi.The trial enrolled 200 patients living with bipolar disorder or schizophrenia who experienced agitation episodes despite being on stable treatment. Over 12 weeks, participants self-administered either 120 mcg of BXCL501, the same dose approved under medical supervision, or a placebo when symptoms arose.The trial tracked adverse events as its primary safety endpoint, while patients or caregivers also provided feedback using a modified global impression of severity scale.Igalmi is also being studied for agitation associated with Alzheimer's dementia, bipolar disorder, and schizophrenia in outpatient and at-home settings. It has received an FDA breakthrough therapy designation for agitation linked to dementia and a fast-track designation for agitation tied to schizophrenia, bipolar disorders, and dementia.BioXcel's stock short interest has also plunged since March, from over 10.6% to 1.8% as of the end of last week, according to Koyfin data.Shares of the company have shed nearly 15% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/firefly-neuroscience-stock-scores-biggest-gain-in-weeks-on-nvidia-brain-platform-boost/chsxnkFRdkQ">Firefly Neuroscience Stock Scores Biggest Gain In Weeks On Nvidia Brain Platform Boost</a>

BioXcel's trial enrolled 200 patients living with bipolar disorder or schizophrenia who experienced agitation episodes despite being on stable treatment. | Representative image via Getty Images

BioXcel Sparks Retail Frenzy As Stock Soars Ahead Of Phase 3 Results For Bipolar, Schizophrenia Drug

Shares surged after hours on Tuesday, making BioXcel the most talked-about stock on Stocktwits, with message volume up 118% in the 24 hours following the announcement.

All Eyes On BioXcel Stock As Phase 3 Data For Bipolar, Schizophrenia Drug Due Today

Shares surged after hours on Tuesday, making BioXcel the most talked-about stock on Stocktwits, with message volume up 118% in the 24 hours following the announcement.


Retail chatter surged around BioXcel Therapeutics early Monday after the company said it received positive preliminary FDA comments ahead of an&nbsp;Aug. 20&nbsp;meeting to discuss expanding Igalmi’s label for at-home use in agitation tied to bipolar disorder and schizophrenia.The FDA’s remarks focused on aligning with the company over the format and content of the upcoming&nbsp;supplemental new drug application (sNDA)&nbsp;submission. BioXcel said it is evaluating the comments and expects to provide an update following the meeting.&nbsp;Currently, Igalmi is approved for hospital or supervised clinical use, and a green light for outpatient administration would open a new, significantly larger commercial opportunity.The regulatory update comes on the heels of BioXcel completing its Serenity At-Home Phase 3 trial earlier this month, with&nbsp;the&nbsp;last patient visits finalized across 22 U.S. sites.&nbsp;The pivotal study enrolled more than 200 patients and is designed to assess the safety of a 120 mcg self-administered dose of BXCL501 for acute agitation episodes in home settings. Top-line data are expected later this quarter and will form the backbone of the planned sNDA filing.The FDA has previously granted BXCL501 Breakthrough Therapy designation for dementia-related agitation and Fast Track status for schizophrenia, bipolar disorder, and dementia.&nbsp;BioXcel has also received two favorable recommendations from its Data Safety Monitoring Board, supporting the drug’s advancement toward regulatory review.Last Friday, H.C. Wainwright boosted its price target on the stock to $10 from $8 while sticking with a Buy rating, pointing to growing excitement around BXCL501.&nbsp;The brokerage firm called the upcoming Serenity trial readout “low-risk” and expects the company&nbsp;to&nbsp;file for an expanded label by the end of the year, with the FDA potentially signing off in the second half of 2026.On Aug. 6, BioXcel said a new paper in Frontiers in Pharmacology highlighted dexmedetomidine, the key ingredient in BXCL501.The study showed it could significantly influence stress-related behaviors in preclinical models, raising the possibility that the drug’s use might extend beyond calming acute agitation to helping manage longer-term psychiatric conditions.On Stocktwits, retail sentiment for BioXcel was described as ‘extremely bullish’ with ‘extremely high’ message volume, making it the platform’s most trending stock.One user urged that “$BTAI could be pushed over $50 this week” if investors “stick together,” adding that the community had the power to make it happen.&nbsp;<stembedurl>https://stocktwits.com/Eastcoasttrader11/message/625574895</stembedurl>Another user noted that if the Aug. 20 meeting went positively, it would signal that Phase 3 data had already come back strong as expected.<stembedurl>https://stocktwits.com/PejalPapa/message/625574210</stembedurl><a href="https://stocktwits.com/symbol/BTAI">BioXcel’s stock</a> has declined 8.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail chatter surged around BioXcel Therapeutics (BTAI) early Monday after the company said it received positive preliminary FDA comments. (Photo credit: Getty Images)

BioXcel Stock In Focus: FDA Issues Positive Early Feedback Ahead Of Key Meeting On Expanded Psychiatric Label 

The update comes as the company wraps up its pivotal Serenity At-Home Phase 3 trial and analysts grow more optimistic on BXCL501’s commercial potential. 

BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Lags Revenue Estimates

BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of -6.52% and -52.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks

Capricor slumps 33% as the FDA rejects its BLA for DMD drug, deramiocel, citing lack of effectiveness data and CMC issues.

BioXcel Therapeutics' Approved Drug For Bipolar Disorders/Schizophrenia Shows No Evidence Of Worsening Or Withdrawal In Post-Marketing Study

BioXcel Therapeutics shares topline results from an Igalmi (dexmedetomidine) sublingual film study. The 180 mcg dose demonstrated favorable safety and efficacy in reducing agitation symptoms.
read...

Bioxcel Therapeutics: Navigating Financial Pressures and Clinical Trials   A Hold Rating Analysis

Mizuho Securities analyst Graig Suvannavejh has maintained their neutral stance on BTAI stock, giving a Hold rating on March 13. Graig Suvannavejh...

BioXcel Therapeutics Announces $25 Million Registered Direct Offering

NEW HAVEN, Conn., March 25, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the Company ) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop...

Bioxcel Therapeutics Faces Market Estimation Risks Amidst Adoption and Access Challenges

Bioxcel Therapeutics (BTAI) has disclosed a new risk, in the Accounting & Financial Operations category. Bioxcel Therapeutics' projections of marke...

BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

BioXcel Therapeutics Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$1.02	--	--	N/A
Q2 '25	-$1.86	-$2.45	-31.90%	MISSED
Q1 '25	-$2.72	-$1.50	44.85%	BEAT
Q4 '24	-$6.23	-$3.57	42.69%	BEAT
Q3 '24	-$0.51	-$5.12	-912.77%	MISSED

BTAI
BioXcel Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest BTAI News

BTAIBioXcel Therapeutics Inc